Annual FCF
-$9.38 M
+$1.17 M+11.10%
December 31, 2022
Summary
- As of February 8, 2025, NAVB annual free cash flow is -$9.38 million, with the most recent change of +$1.17 million (+11.10%) on December 31, 2022.
- During the last 3 years, NAVB annual FCF has risen by +$34.50 thousand (+0.37%).
- NAVB annual FCF is now -115.88% below its all-time high of $59.05 million, reached on December 31, 2017.
Performance
NAVB Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$10.27 M
-$14.89 M-321.95%
September 30, 2023
Summary
- As of February 8, 2025, NAVB quarterly free cash flow is -$10.27 million, with the most recent change of -$14.89 million (-321.95%) on September 30, 2023.
- Over the past year, NAVB quarterly FCF has dropped by -$14.89 million (-321.95%).
- NAVB quarterly FCF is now -115.17% below its all-time high of $67.66 million, reached on March 31, 2017.
Performance
NAVB Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$9.91 M
-$8.33 M-527.59%
September 30, 2023
Summary
- As of February 8, 2025, NAVB TTM free cash flow is -$9.91 million, with the most recent change of -$8.33 million (-527.59%) on September 30, 2023.
- Over the past year, NAVB TTM FCF has dropped by -$8.33 million (-527.59%).
- NAVB TTM FCF is now -113.59% below its all-time high of $72.90 million, reached on March 31, 2017.
Performance
NAVB TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
NAVB Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +11.1% | -321.9% | -527.6% |
| 3 y3 years | +0.4% | -321.9% | -527.6% |
| 5 y5 years | -115.9% | -321.9% | -527.6% |
NAVB Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +11.1% | -321.9% | at low | -527.6% | +6.1% |
| 5 y | 5-year | -9.2% | +11.1% | -321.9% | at low | -527.6% | +10.4% |
| alltime | all time | -115.9% | +74.6% | -115.2% | +76.7% | -113.6% | +81.6% |
Navidea Biopharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$10.27 M(-322.0%) | -$9.91 M(+527.6%) |
| Jun 2023 | - | $4.63 M(-362.6%) | -$1.58 M(-81.3%) |
| Mar 2023 | - | -$1.76 M(-29.7%) | -$8.46 M(-9.7%) |
| Dec 2022 | -$9.38 M(-11.1%) | -$2.51 M(+29.3%) | -$9.38 M(-3.2%) |
| Sep 2022 | - | -$1.94 M(-14.3%) | -$9.69 M(-2.1%) |
| Jun 2022 | - | -$2.26 M(-15.5%) | -$9.90 M(-1.9%) |
| Mar 2022 | - | -$2.67 M(-5.1%) | -$10.09 M(-4.3%) |
| Dec 2021 | -$10.55 M(+22.8%) | -$2.82 M(+31.3%) | -$10.55 M(+1.7%) |
| Sep 2021 | - | -$2.15 M(-12.6%) | -$10.37 M(-6.3%) |
| Jun 2021 | - | -$2.45 M(-21.6%) | -$11.06 M(+3.4%) |
| Mar 2021 | - | -$3.13 M(+18.6%) | -$10.70 M(+24.6%) |
| Dec 2020 | -$8.59 M(-8.8%) | -$2.64 M(-7.0%) | -$8.59 M(-1.1%) |
| Sep 2020 | - | -$2.84 M(+35.6%) | -$8.68 M(+6.1%) |
| Jun 2020 | - | -$2.09 M(+106.1%) | -$8.19 M(-0.2%) |
| Mar 2020 | - | -$1.02 M(-62.8%) | -$8.21 M(-12.3%) |
| Dec 2019 | -$9.41 M(-322.5%) | -$2.73 M(+16.7%) | -$9.35 M(+6.6%) |
| Sep 2019 | - | -$2.34 M(+10.9%) | -$8.78 M(+5.3%) |
| Jun 2019 | - | -$2.11 M(-2.4%) | -$8.34 M(-292.8%) |
| Mar 2019 | - | -$2.17 M(+0.5%) | $4.32 M(+2.2%) |
| Dec 2018 | $4.23 M(-92.8%) | -$2.15 M(+13.2%) | $4.23 M(-4.3%) |
| Sep 2018 | - | -$1.90 M(-118.0%) | $4.42 M(-17.4%) |
| Jun 2018 | - | $10.55 M(-566.7%) | $5.35 M(-149.2%) |
| Mar 2018 | - | -$2.26 M(+15.0%) | -$10.87 M(-118.4%) |
| Dec 2017 | $59.05 M(+1561.1%) | -$1.96 M(+102.6%) | $59.05 M(-6.7%) |
| Sep 2017 | - | -$969.70 K(-82.9%) | $63.27 M(-5.4%) |
| Jun 2017 | - | -$5.67 M(-108.4%) | $66.90 M(-8.2%) |
| Mar 2017 | - | $67.66 M(+2896.8%) | $72.90 M(+1950.6%) |
| Dec 2016 | $3.55 M(-118.6%) | $2.26 M(-15.0%) | $3.55 M(-222.3%) |
| Sep 2016 | - | $2.66 M(+722.5%) | -$2.91 M(-69.9%) |
| Jun 2016 | - | $322.90 K(-119.2%) | -$9.67 M(-42.1%) |
| Mar 2016 | - | -$1.68 M(-60.0%) | -$16.71 M(-12.7%) |
| Dec 2015 | -$19.14 M(-36.9%) | -$4.20 M(+2.3%) | -$19.14 M(-3.3%) |
| Sep 2015 | - | -$4.11 M(-38.8%) | -$19.79 M(-11.8%) |
| Jun 2015 | - | -$6.71 M(+63.2%) | -$22.43 M(-7.6%) |
| Mar 2015 | - | -$4.11 M(-15.2%) | -$24.27 M(-20.0%) |
| Dec 2014 | -$30.32 M(-17.8%) | -$4.85 M(-28.1%) | -$30.32 M(-18.3%) |
| Sep 2014 | - | -$6.75 M(-21.1%) | -$37.12 M(-7.6%) |
| Jun 2014 | - | -$8.55 M(-15.9%) | -$40.18 M(+2.2%) |
| Mar 2014 | - | -$10.16 M(-12.8%) | -$39.32 M(+6.5%) |
| Dec 2013 | -$36.90 M(+50.0%) | -$11.66 M(+18.9%) | -$36.90 M(+13.2%) |
| Sep 2013 | - | -$9.81 M(+27.6%) | -$32.61 M(+16.0%) |
| Jun 2013 | - | -$7.69 M(-0.8%) | -$28.12 M(+9.8%) |
| Mar 2013 | - | -$7.75 M(+5.2%) | -$25.62 M(+4.1%) |
| Dec 2012 | -$24.60 M(+51.4%) | -$7.37 M(+38.8%) | -$24.60 M(-9.0%) |
| Sep 2012 | - | -$5.31 M(+2.4%) | -$27.03 M(+6.0%) |
| Jun 2012 | - | -$5.19 M(-23.0%) | -$25.50 M(+20.7%) |
| Mar 2012 | - | -$6.73 M(-31.3%) | -$21.13 M(+30.0%) |
| Dec 2011 | -$16.25 M(+191.8%) | -$9.80 M(+159.8%) | -$16.25 M(+101.3%) |
| Sep 2011 | - | -$3.77 M(+361.0%) | -$8.07 M(+45.4%) |
| Jun 2011 | - | -$818.60 K(-55.8%) | -$5.55 M(-17.6%) |
| Mar 2011 | - | -$1.85 M(+13.6%) | -$6.74 M(+21.0%) |
| Dec 2010 | -$5.57 M(+237.5%) | -$1.63 M(+29.8%) | -$5.57 M(+32.2%) |
| Sep 2010 | - | -$1.25 M(-37.5%) | -$4.21 M(+22.6%) |
| Jun 2010 | - | -$2.01 M(+195.4%) | -$3.43 M(+84.7%) |
| Mar 2010 | - | -$679.20 K(+149.6%) | -$1.86 M(+12.7%) |
| Dec 2009 | -$1.65 M(-47.7%) | -$272.10 K(-42.9%) | -$1.65 M(-38.9%) |
| Sep 2009 | - | -$476.70 K(+10.4%) | -$2.70 M(-20.4%) |
| Jun 2009 | - | -$431.70 K(-8.0%) | -$3.39 M(-5.0%) |
| Mar 2009 | - | -$469.30 K(-64.5%) | -$3.57 M(+13.0%) |
| Dec 2008 | -$3.16 M | -$1.32 M(+13.3%) | -$3.16 M(+68.2%) |
| Sep 2008 | - | -$1.17 M(+91.7%) | -$1.88 M(+86.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2008 | - | -$608.60 K(+942.1%) | -$1.00 M(-23.0%) |
| Mar 2008 | - | -$58.40 K(+38.4%) | -$1.30 M(-0.7%) |
| Dec 2007 | -$1.31 M(-64.8%) | -$42.20 K(-85.7%) | -$1.31 M(-46.2%) |
| Sep 2007 | - | -$295.30 K(-67.5%) | -$2.44 M(-21.4%) |
| Jun 2007 | - | -$908.20 K(+1247.5%) | -$3.10 M(-0.4%) |
| Mar 2007 | - | -$67.40 K(-94.2%) | -$3.12 M(-16.5%) |
| Dec 2006 | -$3.73 M(+20.1%) | -$1.17 M(+21.7%) | -$3.73 M(+21.0%) |
| Sep 2006 | - | -$960.00 K(+4.3%) | -$3.09 M(-18.8%) |
| Jun 2006 | - | -$920.70 K(+34.7%) | -$3.80 M(+30.9%) |
| Mar 2006 | - | -$683.70 K(+31.1%) | -$2.90 M(-6.5%) |
| Dec 2005 | -$3.11 M(+240.4%) | -$521.50 K(-68.9%) | -$3.11 M(+10.7%) |
| Sep 2005 | - | -$1.68 M(+6942.0%) | -$2.81 M(+79.0%) |
| Jun 2005 | - | -$23.80 K(-97.3%) | -$1.57 M(-13.8%) |
| Mar 2005 | - | -$887.30 K(+300.8%) | -$1.82 M(+99.2%) |
| Dec 2004 | -$913.30 K(-51.7%) | -$221.40 K(-49.3%) | -$913.30 K(-42.9%) |
| Sep 2004 | - | -$436.40 K(+59.0%) | -$1.60 M(+3.8%) |
| Jun 2004 | - | -$274.50 K(-1544.7%) | -$1.54 M(-4.7%) |
| Mar 2004 | - | $19.00 K(-102.1%) | -$1.62 M(-14.5%) |
| Dec 2003 | -$1.89 M(-42.4%) | -$907.30 K(+140.0%) | -$1.89 M(+27.4%) |
| Sep 2003 | - | -$378.10 K(+8.0%) | -$1.48 M(-27.7%) |
| Jun 2003 | - | -$350.00 K(+37.6%) | -$2.05 M(-32.6%) |
| Mar 2003 | - | -$254.40 K(-49.2%) | -$3.04 M(-7.2%) |
| Dec 2002 | -$3.28 M(+839.6%) | -$501.20 K(-47.1%) | -$3.28 M(-5.6%) |
| Sep 2002 | - | -$947.70 K(-29.3%) | -$3.47 M(+65.0%) |
| Jun 2002 | - | -$1.34 M(+174.1%) | -$2.10 M(>+9900.0%) |
| Mar 2002 | - | -$489.30 K(-29.5%) | -$9300.00(-97.3%) |
| Dec 2001 | -$349.00 K(-123.2%) | -$694.10 K(-265.4%) | -$349.00 K(-120.0%) |
| Sep 2001 | - | $419.60 K(-44.4%) | $1.75 M(-16.1%) |
| Jun 2001 | - | $754.50 K(-191.0%) | $2.08 M(+49.1%) |
| Mar 2001 | - | -$829.00 K(-159.1%) | $1.40 M(-6.9%) |
| Dec 2000 | $1.50 M(-20.8%) | $1.40 M(+85.8%) | $1.50 M(+1412.9%) |
| Sep 2000 | - | $755.20 K(+999.3%) | $99.30 K(-115.1%) |
| Jun 2000 | - | $68.70 K(-109.5%) | -$655.90 K(-59.6%) |
| Mar 2000 | - | -$724.60 K(-19.5%) | -$1.62 M(-88.2%) |
| Dec 1999 | $1.90 M(-107.1%) | - | - |
| Jun 1999 | - | -$900.00 K(-60.9%) | -$13.73 M(-31.4%) |
| Mar 1999 | - | -$2.30 M(-59.2%) | -$20.03 M(-25.1%) |
| Dec 1998 | -$26.73 M(+0.5%) | -$5.63 M(+15.0%) | -$26.73 M(-1.3%) |
| Sep 1998 | - | -$4.90 M(-31.9%) | -$27.09 M(-4.6%) |
| Jun 1998 | - | -$7.20 M(-20.0%) | -$28.39 M(+3.3%) |
| Mar 1998 | - | -$9.00 M(+50.3%) | -$27.49 M(+3.4%) |
| Dec 1997 | -$26.59 M(+46.9%) | -$5.99 M(-3.4%) | -$26.59 M(-312.7%) |
| Sep 1997 | - | -$6.20 M(-1.6%) | $12.50 M(-149.4%) |
| Jun 1997 | - | -$6.30 M(-22.2%) | -$25.30 M(+21.6%) |
| Mar 1997 | - | -$8.10 M(-124.5%) | -$20.80 M(+14.9%) |
| Dec 1996 | -$18.10 M(+70.8%) | $33.10 M(-175.2%) | -$18.10 M(-66.4%) |
| Sep 1996 | - | -$44.00 M(+2344.4%) | -$53.80 M(+344.6%) |
| Jun 1996 | - | -$1.80 M(-66.7%) | -$12.10 M(-2.4%) |
| Mar 1996 | - | -$5.40 M(+107.7%) | -$12.40 M(+34.8%) |
| Dec 1995 | -$10.60 M(0.0%) | -$2.60 M(+13.0%) | -$9.20 M(-7.1%) |
| Sep 1995 | - | -$2.30 M(+9.5%) | -$9.90 M(+30.3%) |
| Jun 1995 | - | -$2.10 M(-4.5%) | -$7.60 M(-11.6%) |
| Mar 1995 | - | -$2.20 M(-33.3%) | -$8.60 M(-18.9%) |
| Dec 1994 | -$10.60 M(+35.9%) | -$3.30 M(<-9900.0%) | -$10.60 M(-378.9%) |
| Sep 1994 | - | $0.00(-100.0%) | $3.80 M(-131.9%) |
| Jun 1994 | - | -$3.10 M(-26.2%) | -$11.90 M(+271.9%) |
| Mar 1994 | - | -$4.20 M(-137.8%) | -$3.20 M(-59.0%) |
| Dec 1993 | -$7.80 M(+212.0%) | $11.10 M(-170.7%) | -$7.80 M(-58.7%) |
| Sep 1993 | - | -$15.70 M(-380.4%) | -$18.90 M(+490.6%) |
| Jun 1993 | - | $5.60 M(-163.6%) | -$3.20 M(-63.6%) |
| Mar 1993 | - | -$8.80 M | -$8.80 M |
| Dec 1992 | -$2.50 M | - | - |
FAQ
- What is Navidea Biopharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals annual FCF year-on-year change?
- What is Navidea Biopharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals quarterly FCF year-on-year change?
- What is Navidea Biopharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals TTM FCF year-on-year change?
What is Navidea Biopharmaceuticals annual free cash flow?
The current annual FCF of NAVB is -$9.38 M
What is the all time high annual FCF for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high annual free cash flow is $59.05 M
What is Navidea Biopharmaceuticals annual FCF year-on-year change?
Over the past year, NAVB annual free cash flow has changed by +$1.17 M (+11.10%)
What is Navidea Biopharmaceuticals quarterly free cash flow?
The current quarterly FCF of NAVB is -$10.27 M
What is the all time high quarterly FCF for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high quarterly free cash flow is $67.66 M
What is Navidea Biopharmaceuticals quarterly FCF year-on-year change?
Over the past year, NAVB quarterly free cash flow has changed by -$14.89 M (-321.95%)
What is Navidea Biopharmaceuticals TTM free cash flow?
The current TTM FCF of NAVB is -$9.91 M
What is the all time high TTM FCF for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high TTM free cash flow is $72.90 M
What is Navidea Biopharmaceuticals TTM FCF year-on-year change?
Over the past year, NAVB TTM free cash flow has changed by -$8.33 M (-527.59%)